Study S001809

Comparative Effectiveness of Tirzepatide and Semaglutide in Patients at Cardiovascular Risk With Overweight or Obesity But Without Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol (PDF)

Registration

Registration: NCT07619508
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 100000
Start: 2026-02-10
Primary completion: 2026-06-01
Lead sponsor: Brigham and Women's Hospital
Conditions: Obesity; Overweight
Interventions: DRUG:Tirzepatide; DRUG:Semaglutide
Results posted: FALSE

Registered primary outcomes

Composite of all-cause mortality, myocardial infarction, or stroke. [1 day after prescription fill of exposure or comparator until outcome, end of data, end of study period, death, discontinuation (45 day grace, risk-window), nursing home admission, augmentation/additional exposure or switch to comparator or other GLP1-RA]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.